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Abstract
Cell therapy with bone marrow stem cells (BMSCs) remains a viable option for tissue repair and regeneration. A major challenge for cell therapy
is the limited cell survival after implantation. This study was to investigate the effect of oxidized low-density lipoprotein (ox-LDL, naturally pres-
ent in human blood) on BMSC injury and the effect of MG53, a tissue repair protein, for the improvement of stem cell survival. Rat bone marrow
multipotent adult progenitor cells (MAPCs) were treated with ox-LDL, which caused significant cell death as reflected by the increased LDH
release to the media. Exposure of MAPCs to ox-LDL led to entry of fluorescent dye FM1-43 measured under confocal microscope, suggesting
damage to the plasma membrane. Ox-LDL also generated reactive oxygen species (ROS) as measured with electron paramagnetic resonance
spectroscopy. While antioxidant N-acetylcysteine completely blocked ROS production from ox-LDL, it failed to prevent ox-LDL-induced cell
death. When MAPCs were treated with the recombinant human MG53 protein (rhMG53) ox-LDL induced LDH release and FM1-43 dye entry
were significantly reduced. In the presence of rhMG53, the MAPCs showed enhanced cell survival and proliferation. Our data suggest that mem-
brane damage induced by ox-LDL contributed to the impaired survival of MAPCs. rhMG53 treatment protected MAPCs against membrane dam-
age and enhanced their survival which might represent a novel means for improving efficacy for stem cell-based therapy for treatment of
diseases, especially in setting of hyperlipidemia.
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Introduction
Cell therapy with stem cells remains a viable option for tissue
repair and regeneration [1–3]. Bone marrow-derived mesenchymal
stem cells (BMSCs) are an attractive source for cell therapy
because of the fact that BMSCs can be easily obtained without
ethical concerns, and conveniently expanded ex vivo to clinical
scales in a short time with minimal loss of potency and little (if
any) inherent immunogenicity for adverse immune reactions
because of their immunosuppressive and/or immunomodulatory
properties [4–6]. However, cell therapy with BMSCs has faced
serious challenges because of low viability of the implanted cells
[7–10]. Recent studies have shown that less than 1% of systemi-
cally administered BMSCs are still present for longer than a week
in various organs including lung, heart, kidney, liver, spleen, and
gut following injection [6, 11–14]. Although some factors have
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been considered to cause the poor survival of transplanted cells,
such as inflammation and hypoxia, the exact mechanism(s)
remains largely unknown.
Oxidized-low-density lipoprotein (ox-LDL) is a natural product in
human blood. The serum ox-LDL concentration was estimated to be
0.7 mg/dl in healthy individuals. The serum ox-LDL level was
1.72 mg/dl and 2.36 mg/dl for the patients with stable coronary
artery disease (CAD) and the ones with acute coronary syndrome,
respectively [15–17]. Ox-LDL exhibits significant effects on progeni-
tor cell especially endothelial progenitor cell (EPC) including apopto-
sis induction and suppression of function and therapeutic potential
[18–26]. A variety of mechanisms are involved in the actions of
ox-LDL on the progenitor cells, including up-regulation and/or activation
of MAPK and LOX-1 (a membrane ox-LDL receptor) pathways. In
addition, the cytokines produced by macrophage, leucocyte and plate-
let could indirectly modify the function of stem cells in the presence
of ox-LDL [27].
Previously, we showed that ox-LDL inhibited the proliferation and
differentiation of BMSCs and induced their apoptosis in vitro [28, 29].
We also observed that a significant amount of reactive oxygen spe-
cies (ROS) was generated by ox-LDL in vitro, indicating ROS might
be the cause of cell death. To test this hypothesis, we co-treated cells
with N-acetylcysteine (NAC), a ROS scavenger, to completely block
ROS production. Interestingly, while NAC could protect BMSCs when
ox-LDL was low (5 lg/ml or less), the protective effects of NAC was
abolished when ox-LDL was increased to 10 lg/ml or higher. Of note,
low level of ox-LDL predominantly inhibited proliferation and differen-
tiation of BMSCs, while it largely caused cell death at a level of 20 lg/
ml (comparable to serum ox-LDL level for CAD patients). These data
indicated that a ROS-independent mechanism(s) might contribute to
ox-LDL-induced BMSCs death.
Plasma membrane damage repair is a critical process for cell sur-
vival. Our previous studies have established that MG53 is an essential
gene for membrane repair [30]. MG53, also known as TRIM72, is a
muscle-specific member of tripartite motif-containing (TRIM) super-
family which comprises a RING finger domain, one or two B-boxes
and one or two coiled-coil domain [31]. MG53 acts as a sensor of oxi-
dation to oligomerize and then recruit intracellular vesicles to the
injury site to allow for membrane patch formation [30]. In addition,
we also showed that recombinant human MG53 (rhMG53) could
ameliorate pathology of muscular dystrophy mice when it was admin-
istrated through intravenous injection [32], suggesting a potential
application of rhMG53 in the treatment of diseases with compromised
membrane repair, such as cardiac diseases and muscular dystrophy.
In this study, we suggested that plasma membrane damage
might be a novel mechanism for ox-LDL-induced cell death. We
first demonstrated that ox-LDL could indeed induce membrane
injury to BMSCs by quantitatively detecting the release of intracellu-
lar lactate dehydrogenase (LDH) from the cell and the entry of
fluorescent dye FM1-43 into the cell. To protect BMSCs against
ox-LDL-induced membrane injury, rhMG53 was used to treat the cells.
We showed that rhMG53 could significantly protect membrane
injury to BMSCs by ox-LDL, and enhance their survival. Thus, we
demonstrated for first time that membrane damage contributed to
ox-LDL-induced death of BMSCs and treatment with rhMG53 might
represent a novel approach for enhancing BMSC survival after
transplantation.
Materials and Methods
Preparation of LDL and ox-LDL
Native LDL was prepared from the plasma in healthy human participants
by sodium bromide stepwise density gradient centrifugation. Ox-LDL was
prepared by the exposure of native LDL to copper sulphate (5 lM) at
37°C for 3 hrs. The reaction was stopped by adding EDTA (0.25 mM, final
concentration) as described [29, 33, 34]. Thiobarbituric acid reactive sub-
stances (TBARS) were used as an index of the degree of LDL oxidation.
The TBARS value for ox-LDL was between 40 and 50 nmol malondialde-
hyde/mg protein. TBARS were not detectable in native LDL.
Preparation of rhMG53
Escherichia coli fermentation was used to obtain high quality (>97%
purity) rhMG53 protein as described [32]. The membrane protective
activity of rhMG53 (EC50) from each preparation was determined with
established micro-glass bead injury assay as described [32, 35]. The
rhMG53 concentration for this study was its EC50 as determined by
micro-glass bead injury assay.
Cell culture
Rat bone marrow multipotent adult progenitor cells (MAPCs) were pre-
pared and characterized in Dr. Verfaillie’s laboratory in the Stem Cell
Institute at the University of Leuven, Leuven, Belgium. Phenotypically,
these cells were positive for Oct-4, Rex-1, c-Kit, and Pdgfr-a, and nega-
tive for Sca-1, CD34, CD45, Sox-2 and Nanog [29, 36, 37]. The cells
were cultured with ox-LDL (from 0 to 20 lg/ml) for up to 48 hrs with
and without rhMG53 (50–80 lg/ml depending on the EC50 of each pro-
tein preparation) to determine the cell growth and survival. Native LDL
and PBS served as the controls. To determine the involvement of ROS
in the actions of ox-LDL, experiments were repeated when NAC (1 mM)
was present.
Cell proliferation assay
Rat MAPCs were seeded in a 96-well plate at a density of 1000 cells/
well in the presence of ox-LDL (10 lg/ml) for 12, 24, 36 and 48 hrs.
When 20 lg/ml ox-LDL was used, the cells were cultured for 24 hrs at
a density of 3000 cells /well since the cells could die out quickly.
Bovine serum albumin (BSA) was used as control. To evaluate the
effect of NAC (1 mM) or rhMG53 (50–80 lg/ml depending on the EC50
of each protein preparation) on cell proliferation and survival, each
reagent was mixed in the culture medium 5 min. before exposure to
ox-LDL. At each time-point, the cells were prepared for proliferation
assay using BrdU proliferation Assay Kit (Calbiochem, San Diego, CA,
USA) as per manufacturer’s instruction. All samples were prepared in
duplicates.
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Measurement of ROS formation
Production of extracellular ROS from ox-LDL in the culture system was
quantitatively determined using electron paramagnetic resonance (EPR)
spectroscopy as described [38], and intracellular ROS was detected
using ROS detection reagent 20,70-dichlorodihydrofluorescein diacetate
(H2DCFDA; Life Technologies D399, Carlsbad, CA, USA) dissolved in
ethanol (0.5 mg/100 ll) as per the manufacturer’s instruction. Medium
with PBS was used as background with native LDL as control. To evalu-
ate the effect of NAC on ROS production from ox-LDL, NAC (1 mM)
was mixed with the medium 5 min. prior to adding ox-LDL.
Micro-glass beads cell membrane damage assay
The assay for cell membrane damages was modified from our estab-
lished assay for measuring rhMG53 activity in HEK293 cells [32, 35]. In
brief, rat MAPCs (1 9 106 cells/ml) were treated with extracellular
rhMG53 or control protein (BSA), and then exposed to mechanical
plasma membrane damage by orbital shaking with micro-glass beads.
The level of membrane damage was measured by LDH release from the
cells using a LDH Detection Kit (Takara Mountain View, CA, USA) at
490 nm as per manufacturer’s instruction.
Quantification of LDH released from the cells
induced by ox-LDL
Rat MAPCs were seeded in a 24-well plate at a density of 1 9 104
cells/cm2 in the presence of ox-LDL (from 0 to 20 lg/ml) for up to
48 hrs with or without rhMG53. PBS, native LDL, and BSA were
used as controls. The amount of LDH released from the cells was
measured with LDH Cytotoxicity Detection Kit (cat. #MK401; Takara)
according to the manufacturer’s instruction. Rat MAPCs were seeded
in a 24-well plate at a density of 1 9 104 cells/cm2 in the presence
of ox-LDL (from 0 to 20 lg/ml) for 6, 12 and 24 hrs. PBS and
native LDL were used as controls. After incubating the cells over-
night to allow the cells to adhere, the medium was replaced with
fresh culture medium containing different concentrations of ox-LDL.
The medium of each well was collected at each time-point, and cen-
trifuged at 1000 g for 5 min. Then, the supernatant was carefully
transferred into corresponding wells of a clear 96-well flat bottom
microtiter plate (100 ll/well), and mixed with detection reagent (1:1)
for 30 min. at room temperature. The absorbance of the samples
was measured using an ELISA reader at 490 nm with the reference
wavelength of 690 nm. To determine if rhMG53 could protect the cell
membrane against ox-LDL, the experiments were repeated with the
cells with the presence of rhMG53. BSA was used as the control
protein.
FM1-43 dye entry detection
Rat MAPCs were seeded in the 35 mm Glass Bottom Dishes at a den-
sity of 1 9 104 cells/cm2 and incubated over overnight. The cells were
then treated with ox-LDL 10 lg/ml with or without rhMG53 (at EC50)
for 24 hrs with PBS and BSA as controls. After rinsing with Tyrode’s
solution, the cells were mixed with FM1-43 dye. FM1-43 is membrane
impermeable and becomes fluorescent when it enters injured cells and
binds to cellular lipids [30, 32, 35, 39, 40]. Dye entry into the cells
was monitored continuously with fluorescence confocal microscope
(Zeiss LSM780 Oberkochen, Germany) immediately after mixing with
the dye. Consecutive live cell images were obtained at an interval of
4.1 sec./frame for 100 frames.
Statistical analysis
These data were expressed as mean  SE in all experiments and statis-
tically analyzed with unpaired Student’s t-test (two-sided) for two group
comparison or one-way ANOVA (SigmaStat 2.03; Aspire Software Interna-
tional, Ashburn, VA, USA) followed by post hoc conservative Tukey’s
test for multiple comparisons of three or more groups to minimize Type
I error. When a two-tailed P < 0.05, the difference was considered
statistically significant.
Results
Ox-LDL significantly decreased the growth and
survival of MAPCs
Exposure to ox-LDL dramatically decreased the number of MAPCs
in a concentration-dependent manner (Fig. 1). When ox-LDL con-
centration increased to 10 lg/ml, there was no increase in the cell
number in the culture system. When increased to 20 lg/ml, almost
all the cells died within 24 hrs, suggesting that ox-LDL at concen-
tration compatible to that in CAD patients significantly impaired the
survival of MAPCs. Native LDL had no effect on cell population in
culture.
Fig. 1 ox-LDL impairs MAPCs growth. When MAPCs were cultured in
the presence of ox-LDL (0–10 lg/ml for 0–48 hrs), the cell number
was dramatically decreased in a concentration- and time-dependent
manner. When the cells were exposed to 20 lg/ml ox-LDL, almost all
the cells died within 24 hrs of culture (data not shown). **P < 0.01 as
compared with control (n = 3 independent experiments, data presented
as means  SEM).
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NAC completely blocked ROS production from
ox-LDL, but only partially protected MAPCs
against ox-LDL
A significant amount of extracellular (by EPR) and intracellular ROS
(by H2DCFDA assay) was generated from ox-LDL. NAC treatment
completely blocked both extracellular and intracellular ROS produc-
tion from ox-LDL (up to 20 lg/ml, Fig. 2A and B). Interestingly, NAC
effectively prevented the inhibitory effect of ox-LDL at 1 or 5 lg/ml
on cell population in culture. However, NAC had no protective effect
on MAPCs against ox-LDL at 10 lg/ml or higher (Fig. 2C). Thus the
effect of ox-LDL on MPACs was mediated through ROS production at
low concentrations, while independent of ROS formation at higher but
clinically relevant concentrations in vitro. In addition, to determine
that the deleterious effects are ox-LDL specific, we treated MAPCs
with both native LDL (non-oxidized form of LDL) and saturated LDL
(chemically modified oxidized resistant form of LDL). We observed
that both of them failed to introduce cell death and ROS formation
(data not shown).
Ox-LDL induced cell membrane damage to
MAPCs
Release of intracellular LDH from cell and FM1-43 dye entry into cell
are well-established markers for membrane injury. Exposure to
ox-LDL led to a significantly increased LDH release from MAPCs in
conditioned media in a time- and dose-dependent manner (Fig. 3A),
suggesting that ox-LDL indeed induced membrane damage to
MAPCs. Membrane damage by ox-LDL was further confirmed by
entry of fluorescent dye FM1-43 into the cells that was quantitatively
and dynamically analyzed with a live cell imaging assay. As expected,
no dye entered into the control cells with intact membrane. However,
a significant and rapid dye accumulation inside the cells was observed
when exposed to ox-LDL (10 lg/ml, Fig. 3B).
MG53, not NAC, reduced cell membrane damage
to MAPCs by ox-LDL
MG53 is a specific membrane repairing protein [30, 35, 40–45]. To
ensure that MG53 could also repair membrane damage to MAPCs,
the cells were exposed to mechanical injury with micro-glass beads
with and without rhMG53. As expected, rhMG53 effectively protected
the cells against mechanical membrane damage as reflected by a sig-
nificant reduction in LDH release in a dose-dependent manner
(Fig. 4A). rhMG53 also significantly decreased LDH release from
MAPCs exposed to ox-LDL along with a substantial reduction in FM1-
43 dye entry into the cells (Fig. 4B and C, Movies S1–S4). However,
NAC treatment did not prevent dye entry into the cells exposed to ox-
LDL (Fig. 4C), thus no protection against ox-LDL-induced membrane
damage.
MG53 partially reversed ox-LDL-induced
inhibition of cell proliferation and cell death
After 24 and 48 hrs of culture with ox-LDL (10 lg/ml), the number of
MAPCs in the system remained unchanged (500/cm2), while the cells
A
B C
Fig. 2 NAC blocks ROS generation by ox-
LDL, but fails to rescue cell death at high
concentration of ox-LDL. Ox-LDL (10 or
20 lg/ml) increased ROS production in
the culture media dose dependently as
detected by EPR. The antioxidant NAC
(1 mM) completely blocked ROS produc-
tion from ox-LDL (A). Intracellular ROS
formation detected with 20,70-dichlorodihy-
drofluorescein dictate (H2DCFDA) was
also significantly increased in MAPCs
exposed to ox-LDL in a dose-dependent
manner that was also effectively prevented
with NAC (scale bar: 80 lm; B). However,
NAC treatment only prevented the reduc-
tion in cell number of MAPCs by ox-LDL
at a concentration of 5 lg/ml or less, but
failed to protect the cells against ox-LDL
at the concentration of 10 or higher (C).
**P < 0.01 as compared with control
(n = 3 independent experiments, data pre-
sented as means  SEM).
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grew rapidly in the control group with PBS (Fig. 1). When ox-LDL
concentration increased to 20 lg/ml, the majority of the cells were
dead after 24 hrs. In the presence of rhMG53, the cell population was
significantly increased to 50% and 20% of the control after 24 hrs of
culture with 10 and 20 lg/ml ox-LDL, respectively (Fig. 5A). BrdU
assay demonstrated that ox-LDL significantly inhibited the prolifera-
tion of MAPCs that was substantially reversed by rhMG53 (Fig. 5B).
Discussion
The effects of ox-LDL on its target cells are variable and complex
[46–52]. Low ox-LDL level stimulates proliferation, migration and
adhesion of mouse bone marrow mesenchymal stem cells [53, 54]. It
promotes proliferation of macrophage and smooth muscle cell, and
inhibits apoptosis of macrophage and monocyte [50, 55–60]. On the
other hand, high level of ox-LDL inhibits proliferation and promotes
apoptosis of endothelial cell and EPCs [23, 61, 62] (for the sake of
discussion, ox-LDL concentrations above the serum level of healthy
individuals without CAD or hyperlipidemia were considered ‘high’
ox-LDL levels). Recently, we demonstrated that ox-LDL inhibited prolifer-
ation, induced apoptosis of BMSCs, and attenuated their endothelial
differentiation [28, 29]. In this study, we demonstrated that ox-LDL
produced significant damage to cell membrane of MAPCs and
impaired their survival in vitro as demonstrated by increased LDH
release and FM1-43 dye entry into the cells. The membrane repair
protein rhMG53 significantly protected MAPCs against ox-LDL-
induced membrane injury, and significantly improved their survival.
To our knowledge, this was the first time to show that membrane
damage played an important role in the impaired survival of BMSCs
by ox-LDL.
Ox-LDL interacts with a variety of cells via multiple mechanisms
including activating mitogen-activated protein kinase and E-cadherin/
b-catenin/Tcf pathway, promoting LOX-1, and MCP-1 expression,
downregulating E-selectin and integrin a(v)b(5) expression, and inhib-
iting PI3K/Akt signalling [21, 28, 53, 54, 63, 64]. Another important
mechanism for the actions of ox-LDL is ROS formation and oxidative
stress. ROS generation in the peripheral blood monocytes is
increased in hyperlipidemic patients with elevated plasma ox-LDL
level [65]. ROS formation from ox-LDL was involved in its actions on
MAPCs, including specific stem cell marker Oct-4 expression, prolif-
eration of MAPCs, and their endothelial differentiation [28, 29]. In this
study, we observed that ox-LDL, enhanced intracellular and extracel-
lular ROS production with significantly reduced number of MAPCs
in vitro. NAC completely blocked ROS formation from ox-LDL, but
only prevented the effect of low dose ox-LDL on the growth of MAPCs
without protection against ox-LDL-induced death of MAPCs at a con-
centration of 10 lg/ml or higher. These data suggested that ox-LDL-
induced inhibition of cell proliferation of MAPCs was dependent on
ROS formation, while ox-LDL-induced cell death of MAPCs at the
concentration comparable to serum ox-LDL levels in CAD patients
was independent of ROS production.
Membrane integrity is critical to cell survival and function includ-
ing growth, differentiation and mobility [66–69]. Lipids and phospho-
lipids are important part of cell membrane structure. Ox-LDL interacts
with cell membrane lipids and modifies cell function. Exposure of
endothelial cell to ox-LDL increases membrane stiffness with changes
in their contractility and angiogenic potential because of disruption of
lipid packing of cholesterol-rich membrane domains [70–72]. In this
study, we showed for the first time that ox-LDL produced significant
membrane damage to MAPCs that contributed to their death in vitro.
The role of membrane damage in mediating ox-LDL-induced cell
death was further confirmed by the finding that the specific mem-
brane repair protein rhMG53 significantly reduced cell membrane
damage by ox-LDL, improved the survival of MAPCs and their prolif-
eration in the presence of ox-LDL.
Repair of acute disruptions to the plasma membrane is an impor-
tant aspect of normal cell physiology. MG53 is a critical acute mem-
brane repair molecule. Our previous study has shown that purified
rhMG53 could effectively repair cell membrane damages to skeletal
muscles both in vitro and in vivo [32] . In this study, we showed that
rhMG53 also effectively protect MAPCs against mechanical mem-
brane damage by microglasses and reduced the membrane damages
to MAPCs by ox-LDL. Of note, rhMG53 only partially reversed the
effect of ox-LDL on cell death of MAPCs, suggesting there is still
room for enhancing efficacy for MG53-mediated cell protection. For
example, Kohr et al. elegantly demonstrated that oxidative stress
induced oxidation of MG53 at cysteine 144 residue greatly attenuated
its stability [44]. Thus, we could generate mutant rhMG53 (e.g.
MG53C144S) to enhance the half-life of MG53 in oxidative environment
(ox-LDL), or to modify MG53 with s-nitrosylation [44]. Clearly, other
mechanism(s) is also involved in the impaired survival of MAPCs by
ox-LDL. Indeed, we observed that phosphorylated Akt level was sig-
nificantly decreased in MAPCs exposed to ox-LDL, suggesting that
Akt signalling was also important in the survival of MAPCs (data not
shown).
A B
Fig. 3 ox-LDL induces plasma membrane injury to MAPCs. After 24 hrs
of culture with ox-LDL (10 and 20 lg/ml), there was a significant
increase in the release of intracellular lactate dehydrogenase (LDH) from
MAPC in the conditioned media in a time- and dose-dependent manner
(A) as compared with PBS the control. Exposure to ox-LDL (10 lg/ml)
also substantially increased the entry of fluorescent dye FM1-43 into
the cells as demonstrated with the live confocal microscope. As
expected, no dye entered into the control cells with intact membrane
(B). **P < 0.01 as compared with control at the same time-point
(n = 3 independent experiments, data presented as means  SEM;
scale bar: 20 lm).
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The finding that membrane damage contributed to impaired sur-
vival of MAPCs by ox-LDL might have significant clinical relevance.
One major challenge for cell therapy with BMSCs is the poor in vivo
survival. Identification of the factors contributing to in vivo cell loss
and related mechanism(s) could be a critical initial step to enhancing
cell survival and therapeutic efficacy. Data from this study could
A B
Fig. 5 rhMG53 rescues cell death induced by ox-LDL. When MAPCs were cultured with ox-LDL at the concentration of 20 lg/ml, almost all the cells
died within 24 hrs. However, when rhMG53 was added into the culture system, the cell population was significantly increased to 20% of the control
after 24 hrs of culture with 20 lg/ml ox-LDL. BSA at the same concentration as rhMG53 had no effect on cell population (A). BrdU assay showed
that ox-LDL significantly inhibited the proliferation of MAPCs that was substantially reversed by rhMG53 (B; ox-LDL at 20 lg/ml with 3000 cells/well
with 24 hrs of culture). **P < 0.01 as compared with rhMG53 treatment (n = 3 independent experiments, data presented as means  SEM).
A
C
B
Fig. 4 rhMG53 protects MAPCs against membrane damage following both mechanical injury and ox-LDL treatment. When MAPCs were exposed to
mechanical plasma membrane damage with glass beads, a significant amount of intracellular lactate dehydrogenase (LDH) was released from the
cells. LDH release was significantly decreased from MAPCs exposed to the mechanical membrane injury when rhMG53 was present in a dose-
dependent manner as compared with BSA control (A). The EC50 of rhMG53 was determined to be the protein concentration that reduced the total
LDH release by 50%. Treatment of MAPCs with rhMG53 at EC50 concentration significantly decreased LDH release induced by ox-LDL (20 lg/ml)
from the cells, while there was no effect of BSA on ox-LDL-induced LDH release (B). Quantitative and dynamic analysis with a quantitative live cell
imaging assay showed that exposure to ox-LDL (10 lg/ml) dramatically increased FM1-43 dye accumulation inside the cells that was significantly
reduced by rhMG53, but not by BSA or NAC. The dynamic of FM1-43 dye entry was analyzed by imageJ (more than 200 cells were analyzed for
each condition and each experiment) (C). **P < 0.01 as compared with rhMG53 treatment (n = 3 independent experiments, data presented as
means  SEM; scale bar: 20 lm).
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provide important information on patient selection and preparation
for cell therapy with BMSCs. The majority of patients with myocardial
infarction or stroke who could be ideal candidates for cell therapy
have CAD and hyperlipidemia with elevated ox-LDL level. Optimal
control of hyperlipidemia could improve the survival of transplanted
BMSCs and enhance the outcome for hyperlipidemic patients. Alter-
natively, a membrane protection agent like rhMG53 could serve as an
effective strategy to minimizing the loss of transplanted BMSCs,
especially for hyperlipidemic patients. Investigations are needed to
evaluate the role of ox-LDL and hyperlipidemia in the survival of
transplanted BMSCs and related mechanism(s) in vivo.
Of course, our present study cannot address every question
regarding MG53-mediated stem cell protection. For example, in addi-
tion to membrane damage repair, are there other mechanisms
involved in beneficial effects of MG53? Can MG53 protect ox-LDL-
induced stem cell injury in vivo? For the first question, we have had
preliminary data suggesting that the Akt prosurvival pathway might
be activated by exogenous MG53 application. However, further stud-
ies are required to determine how extracellular application of MG53
can activate intracellular signal. Furthermore, we will take advantage
of hyperlipidemia animal models developed in our group to test the in
vivo function of MG53 on stem cell protection.
In conclusion, we demonstrated that ox-LDL significantly
decreased the survival of MAPCs in part due to induction of mem-
brane damage in vitro. The specific membrane repair protein rhMG53
protected the cells against ox-LDL-induced membrane damages and
enhanced their survival. Data might have important clinical implica-
tion for cell therapy with BMSCs especially for hyperlipidemic
patients.
Acknowledgements
This work was supported by NIH R01 HL094650 (ZL) and American Heart
Association 12SDG12070174 (HZ).
Conflicts of interest
The authors declare that there are no conflicts of interest.
Supporting information
Additional Supporting Information may be found in the online
version of this article:
Movie S1 MAPCs treated with PBS as control.
Movie S2 MAPCs treated with ox-LDL (10 lg/ml).
Movie S3 MAPCs treated with ox-LDL (10 lg/ml) + NAC (1 mM).
Movie S4 MAPCs treated with ox-LDL (10 lg/ml) + rhMG53 (EC50).
References
1. Lalu MM, McIntyre L, Pugliese C, et al.
Safety of cell therapy with mesenchymal
stromal cells (SafeCell): a systematic review
and meta-analysis of clinical trials. PLoS
ONE. 2012; 7: e47559.
2. Mundra V, Gerling IC, Mahato RI. Mesen-
chymal stem cell-based therapy. Mol Pharm.
2013; 10: 77–89.
3. Williams AR, Hare JM. Mesenchymal stem
cells: biology, pathophysiology, translational
findings, and therapeutic implications for
cardiac disease. Circ Res. 2011; 109: 923–
40.
4. Djouad F, Bouffi C, Ghannam S, et al. Mes-
enchymal stem cells: innovative therapeutic
tools for rheumatic diseases. Nat Rev Rheu-
matol. 2009; 5: 392–9.
5. Garcia-Castro J, Trigueros C, Madrenas J,
et al. Mesenchymal stem cells and their use
as cell replacement therapy and disease
modelling tool. J Cell Mol Med. 2008; 12:
2552–65.
6. Parekkadan B, Milwid JM. Mesenchymal
stem cells as therapeutics. Annu Rev Bio-
med Eng. 2010; 12: 87–117.
7. Hong KU, Li QH, Guo Y, et al. A highly sen-
sitive and accurate method to quantify abso-
lute numbers of c-kit+ cardiac stem cells
following transplantation in mice. Basic Res
Cardiol. 2013; 108: 346.
8. Laflamme MA, Murry CE. Regenerating the
heart. Nat Biotechnol. 2005; 23: 845–56.
9. Muller-Ehmsen J, Peterson KL, Kedes L,
et al. Rebuilding a damaged heart: long-
term survival of transplanted neonatal rat
cardiomyocytes after myocardial infarction
and effect on cardiac function. Circulation.
2002; 105: 1720–6.
10. Muller-Ehmsen J, Whittaker P, Kloner RA,
et al. Survival and development of neonatal
rat cardiomyocytes transplanted into adult
myocardium. J Mol Cell Cardiol. 2002; 34:
107–16.
11. Gao J, Dennis JE, Muzic RF, et al. The
dynamic in vivo distribution of bone mar-
row-derived mesenchymal stem cells after
infusion. Cells Tissues Organs. 2001; 169:
12–20.
12. Lee JW, Gupta N, Serikov V, et al. Potential
application of mesenchymal stem cells in
acute lung injury. Expert Opin Biol Ther.
2009; 9: 1259–70.
13. Lee RH, Pulin AA, Seo MJ, et al. Intrave-
nous hMSCs improve myocardial infarction
in mice because cells embolized in lung are
activated to secrete the anti-inflammatory
protein TSG-6. Cell Stem Cell. 2009; 5: 54–
63.
14. Schrepfer S, Deuse T, Reichenspurner H,
et al. Stem cell transplantation: the lung
barrier. Transplant Proc. 2007; 39: 573–6.
15. Imazu M, Ono K, Tadehara F, et al. Plasma
levels of oxidized low density lipoprotein are
associated with stable angina pectoris and
modalities of acute coronary syndrome. Int
Heart J. 2008; 49: 515–24.
16. Itabe H, Ueda M. Measurement of plasma
oxidized low-density lipoprotein and its clini-
cal implications. J Atheros Thromb. 2007;
14: 1–11.
17. Yamashita H, Ehara S, Yoshiyama M, et al.
Elevated plasma levels of oxidized low-den-
sity lipoprotein relate to the presence of
angiographically detected complex and
thrombotic coronary artery lesion morphol-
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
2451
J. Cell. Mol. Med. Vol 18, No 12, 2014
ogy in patients with unstable angina. Circ J.
2007; 71: 681–7.
18. Tie G, Yan J, Yang Y, et al. Oxidized low-
density lipoprotein induces apoptosis in
endothelial progenitor cells by inactivating
the phosphoinositide 3-kinase/Akt pathway.
J Vasc Res. 2010; 47: 519–30.
19. Wu Y, Wang Q, Cheng L, et al. Effect of oxi-
dized low-density lipoprotein on survival and
function of endothelial progenitor cell medi-
ated by p38 signal pathway. J Cardiovas
Pharmacol. 2009; 53: 151–6.
20. Hamed S, Brenner B, Abassi Z, et al.
Hyperglycemia and oxidized-LDL exert a del-
eterious effect on endothelial progenitor cell
migration in type 2 diabetes mellitus.
Thromb Res. 2010; 126: 166–74.
21. Di Santo S, Diehm N, Ortmann J, et al. Oxi-
dized low density lipoprotein impairs
endothelial progenitor cell function by down-
regulation of E-selectin and integrin alpha(v)
beta5. Biochem Biophys Res Commun.
2008; 373: 528–32.
22. Ma FX, Zhou B, Chen Z, et al. Oxidized low
density lipoprotein impairs endothelial pro-
genitor cells by regulation of endothelial
nitric oxide synthase. J Lipid Res. 2006; 47:
1227–37.
23. Wang X, Chen J, Tao Q, et al. Effects of
ox-LDL on number and activity of circulating
endothelial progenitor cells. Drug Chem Tox-
icol. 2004; 27: 243–55.
24. Imanishi T, Hano T, Sawamura T, et al.
Oxidized low-density lipoprotein induces
endothelial progenitor cell senescence, lead-
ing to cellular dysfunction. Clin Exp Pharma-
col Physiol. 2004; 31: 407–13.
25. Zhou B, Ma FX, Liu PX, et al. Impaired ther-
apeutic vasculogenesis by transplantation of
OxLDL-treated endothelial progenitor cells.
J Lipid Res. 2007; 48: 518–27.
26. Imanishi T, Hano T, Matsuo Y, et al. Oxi-
dized low-density lipoprotein inhibits vascu-
lar endothelial growth factor-induced
endothelial progenitor cell differentiation.
Clin Exp Pharmacol Physiol. 2003; 30: 665–
70.
27. Yang H, Mohamed AS, Zhou SH. Oxidized
low density lipoprotein, stem cells, and ath-
erosclerosis. Lipids Health Dis. 2012; 11:
85.
28. Chu L, Hao H, Luo M, et al. Ox-LDL modi-
fies the behaviour of bone marrow stem
cells and impairs their endothelial differenti-
ation via inhibition of Akt phosphorylation.
J Cell Mol Med. 2011; 15: 423–32.
29. Lu T, Parthasarathy S, Hao H, et al. Reactive
oxygen species mediate oxidized low-density
lipoprotein-induced inhibition of oct-4
expression and endothelial differentiation of
bone marrow stem cells. Antioxid Redox
Signal. 2010; 13: 1845–56.
30. Cai C, Masumiya H, Weisleder N, et al.
MG53 nucleates assembly of cell membrane
repair machinery. Nat Cell Biol. 2009; 11:
56–64.
31. Ozato K, Shin DM, Chang TH, et al. TRIM
family proteins and their emerging roles in
innate immunity. Nat Rev Immunol. 2008; 8:
849–60.
32. Weisleder N, Takizawa N, Lin P, et al.
Recombinant MG53 protein modulates ther-
apeutic cell membrane repair in treatment of
muscular dystrophy. Science Transl Med.
2012; 4: 139ra85.
33. Auge N, Nikolova-Karakashian M, Carpen-
tier S, et al. Role of sphingosine 1-phos-
phate in the mitogenesis induced by
oxidized low density lipoprotein in smooth
muscle cells via activation of sphingomyelin-
ase, ceramidase, and sphingosine kinase.
J Biol Chem. 1999; 274: 21533–8.
34. Cominacini L, Garbin U, Davoli A, et al. A
simple test for predisposition to LDL oxida-
tion based on the fluorescence development
during copper-catalyzed oxidative modifica-
tion. J Lipid Res. 1991; 32: 349–58.
35. Zhu H, Lin P, De G, et al. Polymerase trans-
criptase release factor (PTRF) anchors
MG53 protein to cell injury site for initiation
of membrane repair. J Biol Chem. 2011;
286: 12820–4.
36. Breyer A, Estharabadi N, Oki M, et al. Mul-
tipotent adult progenitor cell isolation and
culture procedures. Exp Hematol. 2006; 34:
1596–601.
37. Ulloa-Montoya F, Kidder BL, Pauwelyn KA,
et al. Comparative transcriptome analysis of
embryonic and adult stem cells with
extended and limited differentiation capacity.
Genome Biol. 2007; 8: R163.
38. Zhu X, Zuo L, Cardounel AJ, et al. Char-
acterization of in vivo tissue redox status,
oxygenation, and formation of reactive
oxygen species in postischemic myocar-
dium. Antioxid Redox Signal. 2007; 9:
447–55.
39. McNeil PL, Miyake K, Vogel SS. The endo-
membrane requirement for cell surface
repair. Proc Natl Acad Sci USA. 2003; 100:
4592–7.
40. He B, Tang RH, Weisleder N, et al. Enhanc-
ing muscle membrane repair by gene
delivery of MG53 ameliorates muscular
dystrophy and heart failure in delta-Sarco-
glycan-deficient hamsters. Mol Ther. 2012;
20: 727–35.
41. Cai CX, Weisleder N, Ko JK, et al. Mem-
brane repair defects in muscular dystrophy
are linked to altered interaction between
MG53, caveolin-3, and dysferlin. J Biol
Chem. 2009; 284: 15894–902.
42. Cao CM, Zhang Y, Weisleder N, et al.
MG53 constitutes a primary determinant of
cardiac ischemic preconditioning. Circula-
tion. 2010; 121: 2565–74.
43. Wang X, Xie W, Zhang Y, et al. Cardiopro-
tection of ischemia/reperfusion injury by
cholesterol-dependent MG53-mediated
membrane repair. Circ Res. 2010; 107: 76–
83.
44. Kohr MJ, Evangelista AM, Ferlito M, et al.
S-nitrosylation of TRIM72 at cysteine 144 is
critical for protection against oxidation-
induced protein degradation and cell death.
J Mol Cell Cardiol. 2014; 69: 67–74.
45. X’Avia Chan CY, Wang D, Cadeiras M,
et al. S-nitrosylation of TRIM72 mends the
broken heart: a molecular modifier-mediated
cardioprotection. J Mol Cell Cardiol. 2014;
72C: 292–5.
46. Pervaiz S, Taneja R, Ghaffari S. Oxidative
stress regulation of stem and progenitor
cells. Antioxid Redox Signal. 2009; 11:
2777–89.
47. Rauscher FM, Goldschmidt-Clermont PJ,
Davis BH, et al. Aging, progenitor cell
exhaustion, and atherosclerosis. Circulation.
2003; 108: 457–63.
48. Rizzo M, Kotur-Stevuljevic J, Berneis K,
et al. Atherogenic dyslipidemia and oxida-
tive stress: a new look. Transl Res. 2009;
153: 217–23.
49. Rodriguez C, Slevin M, Rodriguez-Calvo R,
et al. Modulation of endothelium and
endothelial progenitor cell function by low-
density lipoproteins: implication for vascular
repair, angiogenesis and vasculogenesis.
Pathobiology. 2009; 76: 11–22.
50. Sakai M, Miyazaki A, Hakamata H, et al.
Lysophosphatidylcholine plays an essential
role in the mitogenic effect of oxidized
low density lipoprotein on murine macro-
phages. J Biol Chem. 1994; 269: 31430–
5.
51. Salvayre R, Auge N, Benoist H, et al. Oxi-
dized low-density lipoprotein-induced apop-
tosis. Biochim Biophys Acta. 2002; 1585:
213–21.
52. Stocker R, Keaney JF Jr. Role of oxidative
modifications in atherosclerosis. Physiol
Rev. 2004; 84: 1381–478.
53. Zhang F, Wang C, Jing S, et al. Lectin-like
oxidized LDL receptor-1 expresses in mouse
bone marrow-derived mesenchymal stem
cells and stimulates their proliferation. Exp
Cell Res. 2013; 319: 1054–9.
54. Zhang F, Wang C, Wang H, et al. Ox-LDL
promotes migration and adhesion of bone
marrow-derived mesenchymal stem cells via
2452 ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
regulation of MCP-1 expression. Mediators
Inflamm. 2013; 2013: 691023.
55. Eto H, Miyata M, Kume N, et al. Expression
of lectin-like oxidized LDL receptor-1 in
smooth muscle cells after vascular injury.
Biochem Biophys Res Commun. 2006; 341:
591–8.
56. Hamilton JA, Myers D, Jessup W, et al.
Oxidized LDL can induce macrophage sur-
vival, DNA synthesis, and enhanced prolifer-
ative response to CSF-1 and GM-CSF.
Arterioscler Thromb Vasc Biol. 1999; 19:
98–105.
57. Hundal RS, Salh BS, Schrader JW, et al.
Oxidized low density lipoprotein inhibits
macrophage apoptosis through activation of
the PI 3-kinase/PKB pathway. J Lipid Res.
2001; 42: 1483–91.
58. Matsumura T, Sakai M, Kobori S, et al.
Two intracellular signaling pathways for acti-
vation of protein kinase C are involved in oxi-
dized low-density lipoprotein-induced
macrophage growth. Arterioscler Thromb
Vasc Biol. 1997; 17: 3013–20.
59. Namgaladze D, Kollas A, Brune B. Oxidized
LDL attenuates apoptosis in monocytic cells
by activating ERK signaling. J Lipid Res.
2008; 49: 58–65.
60. Yang CM, Chiu CT, Wang CC, et al. Activa-
tion of mitogen-activated protein kinase by
oxidized low-density lipoprotein in canine
cultured vascular smooth muscle cells. Cell
Signal. 2000; 12: 205–14.
61. Chen J, Mehta JL, Haider N, et al. Role of
caspases in Ox-LDL-induced apoptotic cas-
cade in human coronary artery endothelial
cells. Circ Res. 2004; 94: 370–6.
62. Chen XP, Xun KL, Wu Q, et al. Oxidized low
density lipoprotein receptor-1 mediates oxi-
dized low density lipoprotein-induced apop-
tosis in human umbilical vein endothelial
cells: role of reactive oxygen species. Vascul
Pharmacol. 2007; 47: 1–9.
63. Bedel A, Negre-Salvayre A, Heeneman S,
et al. E-cadherin/beta-catenin/T-cell factor
pathway is involved in smooth muscle cell
proliferation elicited by oxidized low-density
lipoprotein. Circ Res. 2008; 103: 694–701.
64. Deambrosis I, Scalabrino E, Deregibus MC,
et al. CD40-dependent activation of phos-
phatidylinositol 3-kinase/AKT pathway inhib-
its apoptosis of human cultured mesangial
cells induced by oxidized LDL. Int J Immu-
nopathol Pharmacol. 2005; 18: 327–37.
65. Vasconcelos EM, Degasperi GR, de Oliveira
HC, et al. Reactive oxygen species generation
in peripheral blood monocytes and oxidized
LDL are increased in hyperlipidemic patients.
Clin Biochem. 2009; 42: 1222–7.
66. Glover L, Brown RH Jr. Dysferlin in mem-
brane trafficking and patch repair. Traffic.
2007; 8: 785–94.
67. Idone V, Tam C, Andrews NW. Two-way
traffic on the road to plasma membrane
repair. Trends Cell Biol. 2008; 18: 552–9.
68. Martin KA, Siefert JL, Yerrapragada S,
et al. Cyanobacterial signature genes. Pho-
tosynth Res. 2003; 75: 211–21.
69. McNeil PL, Kirchhausen T. An emergency
response team for membrane repair. Nat
Rev Mol Cell Biol. 2005; 6: 499–505.
70. Levitan I, Gooch KJ. Lipid rafts in mem-
brane-cytoskeleton interactions and control
of cellular biomechanics: actions of oxLDL.
Antioxid Redox Signal. 2007; 9: 1519–34.
71. Levitan I, Shentu TP. Impact of oxLDL on
cholesterol-rich membrane rafts. J Lipids.
2011; 2011: 730209.
72. Shentu TP, Titushkin I, Singh DK, et al. ox-
LDL-induced decrease in lipid order of mem-
brane domains is inversely correlated with
endothelial stiffness and network formation.
Am J Physiol Cell Physiol. 2010; 299: C218–
29.
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
2453
J. Cell. Mol. Med. Vol 18, No 12, 2014
